Phase 4 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body (stage IIIB to stage IV)
- People whose overall health and ability to carry out daily activities falls within the range measured by a standard medical scale called ECOG, from fully active (0) to completely dependent (4)
- People whose lung cancer has been confirmed through a tissue or cell sample taken from the tumour
- People whose cancer has a specific genetic change called an ALK rearrangement, confirmed by an approved medical test
- People who have either not yet received chemotherapy, or who have received one round of platinum-based chemotherapy
- People who have cancer that has spread to the brain or the lining around the brain, provided those areas are not causing symptoms, have been stable for at least 2 weeks, and do not require steroid treatment
- People who have at least one area of cancer that can be measured using standard imaging guidelines (called RECIST 1.1) before treatment begins
- People who have signed an approved consent form before any study-related procedures begin
- People already participating in another observational study may still be eligible for this trial
- People receiving local radiotherapy for pain management may still be eligible
Who may not be able to join:
- People with another serious medical condition that the doctor leading the trial believes could be made worse by the study drug
- People who have taken medications that affect how the body processes a liver enzyme called CYP3A4, or medications that may affect heart rhythm, within the 14 days before starting the trial or during the trial (confirm with trial site for the specific list of medications)
- People with any significant health condition or situation that could interfere with the trial itself, with absorbing oral medications, or that the lead doctor believes would create an unacceptable health risk during participation
- People facing psychological, family, social, or geographic circumstances that might make it difficult to follow the trial requirements or attend follow-up appointments — these situations would be discussed before a decision is made about trial entry
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: A.J. van der Wekken, PhD, University Medical Center Groningen
Phone: +31503616161
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Median progression free survival (mPFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.